STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES
The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WARNER, KEVIN ZHANG, STEVEN SARPOTDAR, PRAMOD AHLUWALIA, GURPREET KUANG, AMY |
| description | The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
La présente invention concerne des formulations de crème stabilisées d'oxymétazoline, et leurs utilisations. La présente invention concerne également un procédé de traitement d'érythème facial associé à la rosacée chez un patient ayant besoin d'un tel traitement, lequel procédé consistant en l'administration topique, une fois ou deux fois par jour sur le site d'érythème sur le visage du patient, d'une composition pharmaceutique comprenant 0,5 %, 1,0 % ou 1,5 % d'oxymétazoline ou d'un sel pharmaceutiquement acceptable de celle-ci comme principe actif unique. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA2951725C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA2951725C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA2951725C3</originalsourceid><addsrcrecordid>eNrjZDAJDnF08vTxjHJ1UfCPiPR1DXGM8vfx9HNVcPMP8g31cQzx9PcLVnD0c1EI8XD1DFIIDXYN5mFgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORpamhuZGps7GhFUAAGTlJvQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES</title><source>esp@cenet</source><creator>WARNER, KEVIN ; ZHANG, STEVEN ; SARPOTDAR, PRAMOD ; AHLUWALIA, GURPREET ; KUANG, AMY</creator><creatorcontrib>WARNER, KEVIN ; ZHANG, STEVEN ; SARPOTDAR, PRAMOD ; AHLUWALIA, GURPREET ; KUANG, AMY</creatorcontrib><description>The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
La présente invention concerne des formulations de crème stabilisées d'oxymétazoline, et leurs utilisations. La présente invention concerne également un procédé de traitement d'érythème facial associé à la rosacée chez un patient ayant besoin d'un tel traitement, lequel procédé consistant en l'administration topique, une fois ou deux fois par jour sur le site d'érythème sur le visage du patient, d'une composition pharmaceutique comprenant 0,5 %, 1,0 % ou 1,5 % d'oxymétazoline ou d'un sel pharmaceutiquement acceptable de celle-ci comme principe actif unique.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220607&DB=EPODOC&CC=CA&NR=2951725C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76419</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220607&DB=EPODOC&CC=CA&NR=2951725C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WARNER, KEVIN</creatorcontrib><creatorcontrib>ZHANG, STEVEN</creatorcontrib><creatorcontrib>SARPOTDAR, PRAMOD</creatorcontrib><creatorcontrib>AHLUWALIA, GURPREET</creatorcontrib><creatorcontrib>KUANG, AMY</creatorcontrib><title>STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES</title><description>The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
La présente invention concerne des formulations de crème stabilisées d'oxymétazoline, et leurs utilisations. La présente invention concerne également un procédé de traitement d'érythème facial associé à la rosacée chez un patient ayant besoin d'un tel traitement, lequel procédé consistant en l'administration topique, une fois ou deux fois par jour sur le site d'érythème sur le visage du patient, d'une composition pharmaceutique comprenant 0,5 %, 1,0 % ou 1,5 % d'oxymétazoline ou d'un sel pharmaceutiquement acceptable de celle-ci comme principe actif unique.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAJDnF08vTxjHJ1UfCPiPR1DXGM8vfx9HNVcPMP8g31cQzx9PcLVnD0c1EI8XD1DFIIDXYN5mFgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORpamhuZGps7GhFUAAGTlJvQ</recordid><startdate>20220607</startdate><enddate>20220607</enddate><creator>WARNER, KEVIN</creator><creator>ZHANG, STEVEN</creator><creator>SARPOTDAR, PRAMOD</creator><creator>AHLUWALIA, GURPREET</creator><creator>KUANG, AMY</creator><scope>EVB</scope></search><sort><creationdate>20220607</creationdate><title>STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES</title><author>WARNER, KEVIN ; ZHANG, STEVEN ; SARPOTDAR, PRAMOD ; AHLUWALIA, GURPREET ; KUANG, AMY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA2951725C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>WARNER, KEVIN</creatorcontrib><creatorcontrib>ZHANG, STEVEN</creatorcontrib><creatorcontrib>SARPOTDAR, PRAMOD</creatorcontrib><creatorcontrib>AHLUWALIA, GURPREET</creatorcontrib><creatorcontrib>KUANG, AMY</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WARNER, KEVIN</au><au>ZHANG, STEVEN</au><au>SARPOTDAR, PRAMOD</au><au>AHLUWALIA, GURPREET</au><au>KUANG, AMY</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES</title><date>2022-06-07</date><risdate>2022</risdate><abstract>The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
La présente invention concerne des formulations de crème stabilisées d'oxymétazoline, et leurs utilisations. La présente invention concerne également un procédé de traitement d'érythème facial associé à la rosacée chez un patient ayant besoin d'un tel traitement, lequel procédé consistant en l'administration topique, une fois ou deux fois par jour sur le site d'érythème sur le visage du patient, d'une composition pharmaceutique comprenant 0,5 %, 1,0 % ou 1,5 % d'oxymétazoline ou d'un sel pharmaceutiquement acceptable de celle-ci comme principe actif unique.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA2951725C |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A20%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WARNER,%20KEVIN&rft.date=2022-06-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA2951725C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |